By Nigam Arora
MANE is long from $84.88. It is trading up 13% today at $122.69 as of this writing.
Huge Opportunity
There is a large market opportunity. Approximately 50 million American men experience pattern hair loss. If approved, VDPHL01 could become the first new FDA approved oral treatment for pattern hair loss in nearly 30 years.
Trial Results
MANE just announced positive Phase 3 results for VDPHL01, its oral treatment for male pattern hair loss.
Here are the key points:
- All primary and secondary endpoints were met with high statistical significance in a Phase 3 trial involving 536 men.
- After six months, hair counts increased by 28.6 hairs/cm² with once daily dosing and 36.4 hairs/cm² with twice daily dosing, compared with 6.6 hairs/cm² for placebo.
- About 79% to 85% of treated participants reported better hair coverage, compared with 35% of those receiving placebo.
- Statistically significant improvements were seen as early as two months.
- No treatment related serious adverse events or cardiac adverse events of special interest were reported.
- These results build on positive findings from an earlier Phase 2/3 trial, bringing MANE closer to a potential FDA submission and approval.
What Is Next
Longer term 12 month safety data are expected later in 2026, followed by results from the trial in women during the first half of 2027.
Overall, the results are encouraging for MANE. However, the eventual move in stock will depend on FDA approval.
The Plan
The plan is to add on any major pullback if it is not related to a company specific issue but related to a general pullback in the market.
Biotech Caution
MANE is a biotech stock. The usual biotech caution applies. This is a very high reward and high risk position. Please see the Full Core Position Size and Speculative Positions sections in the Trade Management Guidelines.
What To Do Now
Those in MANE and have previously taken partial profits may consider continuing to hold.
Those in MANE who have not taken partial profits may consider taking partial profits.
Those not in MANE may consider waiting for a new signal. Join ZYX Buy to receive an alert when there is a new signal. Click here to start a 30 day free trial.
Why To Take Partial Profits?
The Arora Report system has been optimized in every aspect to maximize the wealth you generate over your lifetime. Unrealized profits can quickly disappear, especially in biotech stocks. For this reason, The Arora Report system is structured to realize partial profits on rips and add on dips while maintaining a core quantity. When appropriate, The Arora Report also utilizes billionaire and hedge fund techniques to trade around positions. Trade around positions can dramatically increase profits and reduce your risks. Please see Trade Management Guidelines to learn more about trade around positions.
As a reference, 270 profit taking signals have been realized in 2026 alone. In 2025, 448 profit taking signals were given. It is important to note that this is not just luck. The Arora Report has given thousands of profit taking signals over nearly two decades.
Taking partial profits is also a protection strategy for the portfolio. The Arora Report has an innovative multi layer sophisticated system that includes profit taking, position size, stop zones, buy zones, target zones, hedging, and most importantly, the proprietary Arora Protection Band.
Signal Limited is a Signal(s) with a great record in similar situations but does not meet all of the stringent criteria for a Signal. Typically Signal Limited has higher risk-reward compared to a Signal over the short term.
Build the Core Model Portfolio gradually, and set your own alarms in your brokerage account for Core Model Portfolio positions. Use Signal Limited positions to surround the Core Model Portfolio positions. See the Main Menu for the Core Model Portfolio.
To take a free 30-day trial to paid services to gain access to more opportunities, please click here.
This post was just published on October 19, 2026 in ZYX Buy Change Alert.
Markets can generate substantial wealth for knowledgeable investors. NOW YOU TOO CAN ALSO SPECTACULARLY SUCCEED AT MEETING YOUR GOALS WITH THE HELP OF THE ARORA REPORT. You are receiving less than 1% of the content from our paid services. …TO RECEIVE REMAINING 99%, INCLUDING MANY ATTRACTIVE INVESTMENT OPPORTUNITIES AND SIGNALS IN REAL TIME, TAKE A FREE
TRIAL TO PAID SERVICES.
The Arora Report is one of the only major global investment newsletters that does not employ a single salesperson—because it does not need to. While competitors rely on high-pressure sales tactics, The Arora Report grows purely through results, with satisfied members recommending it to their family and friends.
Join the service that investors trust the most and recommend to family and friends.
Please click here to take advantage of a FREE 30 day trial.
Nigam Arora
Nigam Arora is known for his accurate stock market calls. Nigam is a distinguished master of the macro. He is a popular columnist with over 100 million page views, an engineer, and nuclear physicist by background. Nigam has founded two Inc. 500 fastest growing companies and has been involved in over 50 entrepreneurial ventures. He is the developer of Theory ZYX of Successful Change Management and is the author of the book on Theory ZYX, as well as the developer of the ZYX Change Method for Investing.
